Clinical Trial Update: Study of Inhaled Iloprost for the Treatment of Pulmonary Hypertension After Repair of Congenital Heart Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating inhaled iloprost for pulmonary hypertension after repair of congenital heart disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Hypertension

Drugs mentioned

• Iloprost (Ventavis) (Iloprost)

Snippet

Sponsor: Shanghai Jiao Tong University School of Medicine | Conditions: Pulmonary Hypertension | Phase 2 | Status: COMPLETED